Integra Lifesciences Holdings Corp [IART] stock is trading at $24.54, up 3.54%. An important factor to consider is whether the stock is rising or falling in short-term value. The IART shares have gain 7.02% over the last week, with a monthly amount glided 25.85%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Integra Lifesciences Holdings Corp [NASDAQ: IART] stock has seen the most recent analyst activity on October 07, 2024, when BTIG Research upgraded its rating to a Neutral. Previously, Citigroup downgraded its rating to Sell on July 30, 2024, and dropped its price target to $23. On July 30, 2024, downgrade downgraded it’s rating to Sell but maintained its price target of $22 on the stock. Wells Fargo downgraded its rating to a Equal Weight and decreased its price target to $25 on May 07, 2024. Oppenheimer downgraded its rating to a Perform. Citigroup upgraded its rating to Neutral for this stock on April 03, 2024, but kept the price target unchanged to $38. In a note dated December 05, 2023, Wells Fargo upgraded an Overweight rating on this stock and boosted its target price from $40 to $49.
Integra Lifesciences Holdings Corp [IART] stock has fluctuated between $16.81 and $45.42 over the past year. Currently, Wall Street analysts expect the stock to reach $43 within the next 12 months. Integra Lifesciences Holdings Corp [NASDAQ: IART] shares were valued at $24.54 at the most recent close of the market. An investor can expect a potential return of 75.22% based on the average IART price forecast.
Analyzing the IART fundamentals
Integra Lifesciences Holdings Corp [NASDAQ:IART] reported sales of 1.56B for the trailing twelve months, which represents a drop of -0.41%. Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at 0.06%, Pretax Profit Margin comes in at -0.01%, and Net Profit Margin reading is -0.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.0 and Total Capital is 0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.92 points at the first support level, and at 23.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.86, and for the 2nd resistance point, it is at 25.18.
Ratios To Look Out For
For context, Integra Lifesciences Holdings Corp’s Current Ratio is 1.20. On the other hand, the Quick Ratio is 0.73, and the Cash Ratio is 0.24. Considering the valuation of this stock, the price to sales ratio is 1.25, the price to book ratio is 1.24.
Transactions by insiders
Recent insider trading involved Mosebrook Jeffrey, SVP, Fin & Princ Acct Officer, that happened on Aug 19 ’24 when 1191.0 shares were sold. Exec. Chairman of the Board, ESSIG STUART completed a deal on May 23 ’24 to buy 52641.0 shares. Meanwhile, Director HILL BARBARA B bought 36350.0 shares on May 21 ’24.
